For example, synthetic cancer neoantigen long peptide vaccines formulated with a toll-like receptor 3 (TLR3) ligand poly-ICLC (polyinosinic and polycytidylic acid) induced strong anti-cancer immunity and clinical response [275]. This evidence concerns the gene TLR3 and cancer.